Active Participants14877% Female · 23% Male
Avg Weight Loss (12 Weeks)15.92 kgFrom program start
Most Used PeptideRetatrutideUsed by 71.45% of cohort
Avg Program Duration10.4 weeksAverage total duration
Class Action Linked19%Participants linked
Compound Overview
Retatrutide
Usage71.45% (106)Participants106Avg Weekly Dose2.0 mg – 5 mgAvg Duration12 weeks
Avg Weight Change (12 Weeks)-15.92 kg
Tirzepatide
Usage14.80% (22)Participants22Avg Weekly Dose2.5 mg – 7.5 mgAvg Duration12 weeks
Avg Weight Change (12 Weeks)-12.86 kg
Semaglutide
Usage9.52% (14)Participants14Avg Weekly Dose1.0 mg – 2.4 mgAvg Duration12 weeks
Avg Weight Change (12 Weeks)-8.19 kg
Cagrilintide
Usage4.23% (6)Participants6Avg Weekly Dose2.0 mg – 4.0 mgAvg Duration12 weeks
Avg Weight Change (12 Weeks)-6.42 kg
Compound Usage Mix
148Total
Retatrutide 71.45% (106)
Tirzepatide 14.80% (22)
Semaglutide 9.52% (14)
Cagrilintide 4.23% (6)
Avg Weight Change by Compound (12 Weeks)
Weekly Weight Change Trend by Compound
RetatrutideTirzepatideSemaglutideCagrilintide
Compound Comparison Table
| Compound | Cohort Size | Dose Range (Weekly) | Avg Duration | Avg Weight Change |
|---|---|---|---|---|
| Retatrutide | 106 (71.45%) | 2.0 mg – 5 mg | 12 weeks | -15.92 kg |
| Tirzepatide | 22 (14.80%) | 2.5 mg – 7.5 mg | 12 weeks | -12.86 kg |
| Semaglutide | 14 (9.52%) | 1.0 mg – 2.4 mg | 12 weeks | -8.19 kg |
| Cagrilintide | 6 (4.23%) | 2.0 mg – 4.0 mg | 12 weeks | -6.42 kg |
All data anonymised. Individual results may vary. June 2026 research transparency report. Not medical advice.